Lowell JA, Farber MJ, Sultan K. Back to the drawing board: Overview of the next generation of combination therapy for inflammatory bowel disease. World J Gastroenterol 2024; 30(25): 3182-3184 [PMID: 39006384 DOI: 10.3748/wjg.v30.i25.3182]
Corresponding Author of This Article
Jeffrey A Lowell, MD, PhD, Doctor, Department of Medicine, Zucker School of Medicine at Hofstra, North Shore University Hospital-Long Island Jewish Medical Center, 300 Community Drive, Manhasset, NY 11030, United States. jlowell@northwell.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jul 7, 2024; 30(25): 3182-3184 Published online Jul 7, 2024. doi: 10.3748/wjg.v30.i25.3182
Back to the drawing board: Overview of the next generation of combination therapy for inflammatory bowel disease
Jeffrey A Lowell, Michael J Farber, Keith Sultan
Jeffrey A Lowell, Department of Medicine, Zucker School of Medicine at Hofstra, North Shore University Hospital-Long Island Jewish Medical Center, Manhasset, NY 11030, United States
Michael J Farber, Preclinical Studies, New York Institute of Technology College of Osteopathic Medicine, Glen Head, NY 11545, United States
Keith Sultan, Division of Gastroenterology, Northwell Health, North Shore University Hospital and Long Island Jewish Medical Center, Great Neck, NY 10021, United States
Author contributions: Lowell JA, Farber MJ, and Sultan K conceptualized the editorial response; Lowell JA drafted the original manuscript. All authors edited subsequent revisions.
Conflict-of-interest statement: The authors declare no conflicts of interest in relation to this letter.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jeffrey A Lowell, MD, PhD, Doctor, Department of Medicine, Zucker School of Medicine at Hofstra, North Shore University Hospital-Long Island Jewish Medical Center, 300 Community Drive, Manhasset, NY 11030, United States. jlowell@northwell.edu
Received: May 1, 2024 Revised: May 27, 2024 Accepted: June 12, 2024 Published online: July 7, 2024 Processing time: 61 Days and 5.6 Hours
Abstract
Inflammatory bowel disease (IBD) is entering a potentially new era of combined therapeutics. Triantafillidis et al provide an insightful review of the current state of combination therapy, with a focus on the use of a combined biologic and immunomodulator, as well as emerging data on the future potential of dual-biologic therapy (DBT). While current evidence for DBT is limited, encouraging safety profiles and ongoing trials suggest a brighter future for this approach. The importance of controlled trials should be stressed in establishing new treatment paradigms. Ongoing prospective randomized trials of DBT and perhaps future combinations of biologics and small molecule therapies will hopefully guide the next generation of IBD care.
Core Tip: Triantafillidis et al thoroughly collate important studies summarizing the available evidence supporting the combination of various therapeutics used in the treatment of inflammatory bowel disease (IBD). Specifically highlighted is the importance of exploring combination therapy with biologics and immunomodulators, and in particular the emerging role of dual-biologic therapy (DBT). Given that current evidence for DBT is limited and new biologics continue to be developed, there is an urgent need for high-quality prospective trials to establish new treatment paradigms for the next generation of IBD care.
